Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 4/20 | 0.42 |
| ▸ | PLG | P00747 | 2/20 | 0.42 |
| ▸ | PLAT | P00750 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2216214 | 0.89 | CYP17A1 (0.41) | CHRM1CYP17A1MAP4K4 | |
| SCHEMBL2216413 | 0.88 | CYP17A1 (0.49) | JAK2CYP17A1MAP4K4MEN1KMT2A | |
| SCHEMBL2215354 | 0.86 | PLAU (0.43) | PLAUPLGPLATSLC2A1POLB | |
| SCHEMBL2213283 | 0.86 | PLG (0.42) | PLAUPLGPLATCHRM1CYP17A1 | |
| SCHEMBL2213436 | 0.86 | CYP17A1 (0.43) | CHRM1CYP17A1MAP4K4 | |
| SCHEMBL2214224 | 0.85 | BCL2 (0.43) | CHRM1CYP17A1 | |
| SCHEMBL2212325 | 0.84 | JAK2 (0.41) | PLAUPLGPLATJAK2CHRM1 | |
| SCHEMBL2876730 | 0.84 | PLAU (0.52) | PLAUPLGPLATMAP4K2SMN1; SMN2 | |
| SCHEMBL2214428 | 0.83 | NAMPT (0.46) | PLAUPLGPLATSLC2A1POLB | |
| SCHEMBL2876734 | 0.83 | BCDIN3D (0.42) | PLAUPLGPLATCYP3A4MAP4K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797096-B1 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7745446-B2 | Pyrazolo[1,5-c]pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | ALTANA PHARMA AG (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254046-A1 | Novel Pyrazolopyrimidines | MCL1, RARS2, CDK4 | PLAU 4610/4885PLG 4568/4885PLAT 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.